曲美他嗪对冠心病合并心力衰竭患者心功能及T淋巴细胞亚群的影响

Effect of trimetazidine on cardiac function and T lymphocyte subsets in patients with coronary heart disease and heart failure

目的探讨曲美他嗪对冠心病合并心力衰竭患者心功能及T淋巴细胞亚群的影响。方法选取长沙市第四医院心内科2018年1月—2020年5月收治的冠心病合并心力衰竭患者104例,采用随机数字表法分为对照组与研究组,各52例。对照组给予常规治疗,研究组在对照组基础上给予曲美他嗪治疗。比较2组临床疗效,治疗前后左心室射血分数(LVEF)、左心室收缩末期内径(LVESD)、左心室舒张末期内径(LVEDD)、CD_(4)^(+)细胞分数、CD_(8)^(+)细胞分数、CD_(4)^(+)/CD_(8)^(+)细胞比值,并观察2组不良反应发生情况。结果研究组总有效率高于对照组(P<0.05)。治疗前2组LVEF、LVESD、LVEDD比较,差异无统计学意义(P>0.05);治疗后研究组LVEF高于对照组,LVESD、LVEDD低于对照组(P<0.05)。治疗前2组CD_(4)^(+)细胞分数、CD_(8)^(+)细胞分数、CD_(4)^(+)/CD_(8)^(+)细胞比值比较,差异无统计学意义(P>0.05);治疗后研究组CD_(4)^(+)细胞分数、CD_(4)^(+)/CD_(8)^(+)细胞比值低于对照组(P<0.05);2组CD_(8)^(+)细胞分数比较,差异无统计学意义(P>0.05)。2组不良反应发生率比较,差异无统计学意义(P>0.05)。结论曲美他嗪治疗冠心病合并心力衰竭患者的临床疗效确切,可改善心功能,调节T细胞亚群,加速病情恢复进程,且安全性较高。

Objective To investigate the effect of trimetazidine on cardiac function and T lymphocyte subsets in patients with coronary heart disease and heart failure.Methods A total of 104 cases of patients with coronary heart disease and heart failure were selected from January 2018 to May 2020 in Changsha City Fourth Hospital,which were divided into control group and study group according to random number table,52 cases respectively.The control group was given routine treatment,and the study group was treated with trimetazidine on the basis of the control group.The clinical efficacy of the two groups was compared.The left ventricular ejection fraction(LVEF),the left ventricular end systolic diameter(LVESD),the left ventricular end diastolic diameter(LVEDD),CD_(4)^(+)cell fraction,CD_(8)^(+)cell fraction,CD_(4)^(+)/CD_(8)^(+)cell ratio were compared before and after treatment,and the adverse reactions were observed in the two groups.Results The total effective rate of the study group was higher than that of the control group(P<0.05).There was no significant difference in LVEF,LVESD and LVEDD between the two groups before treatment(P>0.05);after treatment,the treatment group of LVEF was higher than control group,LVESD and LVEDD were lower than those of the control group(P<0.05).Before treatment,there was no significant difference in CD_(4)^(+)cell fraction,CD_(8)^(+)cell fraction and CD_(4)^(+)/CD_(8)^(+)cell ratio between the two groups(P>0.05);after treatment,the CD_(4)^(+)cell fraction and the ratio of CD_(4)^(+)/CD_(8)^(+)cells in the study group were lower than those in the control group(P<0.05);There was no significant difference in CD_(8)^(+)cell fraction between the two groups(P>0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion Trimetazidine can improve cardiac function,regulate T cell subsets,accelerate the recovery process of the disease,and with high safety.